Renaissance Technologies LLC Has $3.17 Million Position in Autolus Therapeutics PLC Sponsored ADR $AUTL

Key Points

• Renaissance Technologies reduced its Autolus Therapeutics stake by 26% in the first quarter, selling 805,905 shares but retaining 2.30 million shares worth approximately $3.17 million. Institutional investors collectively own 72.83% of the company.
• Analyst sentiment remains generally positive, with Autolus holding a consensus “Moderate Buy” rating and an average price target of $8.75; HC Wainwright set a $10 target and maintained a Buy rating.
• AUTL shares recently rose 5.5% to open at $2.11. The company reported a quarterly loss of $0.27 per share, slightly better than estimates, while revenue of $26.22 million was roughly in line with forecasts.

Renaissance Technologies LLC cut its stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 26.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,299,499 shares of the company's stock after selling 805,905 shares during the quarter. Renaissance Technologies LLC owned approximately 0.86% of Autolus Therapeutics worth $3,173,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in shares of Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company's stock worth $88,000 after purchasing an additional 11,289 shares in the last quarter. Invesco Ltd. grew its stake in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after buying an additional 11,381 shares during the last quarter. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the second quarter worth approximately $28,000. R Squared Ltd increased its holdings in shares of Autolus Therapeutics by 48.4% during the first quarter. R Squared Ltd now owns 39,575 shares of the company's stock worth $55,000 after buying an additional 12,915 shares in the last quarter. Finally, Independent Advisor Alliance bought a new position in shares of Autolus Therapeutics in the fourth quarter valued at approximately $28,000. Institutional investors and hedge funds own 72.83% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AUTL. Wall Street Zen raised Autolus Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday. Jefferies Financial Group upgraded Autolus Therapeutics to a "strong-buy" rating in a research report on Monday, April 20th. Weiss Ratings lowered Autolus Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Friday, July 31st. Finally, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Autolus Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $8.75.

Autolus Therapeutics Trading Up 5.5%

Shares of AUTL stock opened at $2.11 on Friday. Autolus Therapeutics PLC Sponsored ADR has a 1 year low of $1.17 and a 1 year high of $2.52. The firm's 50 day moving average is $1.59 and its 200-day moving average is $1.54. The firm has a market capitalization of $561.59 million, a price-to-earnings ratio of -1.94 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The business had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. On average, equities research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.86 earnings per share for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company's leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source